Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study

Asim Amin; Elizabeth R. Plimack; Marc S. Ernstoff; Lionel D. Lewis; Todd M. Bauer; David F. McDermott; Michael Carducci; Christian Kollmannsberger; Brian I. Rini; Daniel Y. C. Heng; Jennifer Knox; Martin H. Voss; Jennifer Spratlin; Elmer Berghorn; Lingfeng Yang; Hans J. Hammers

doi:10.1186/s40425-019-0559-3

Citation Tools

This article has a correction. Please see:

Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study - December 01, 2018

PDF

Correction

Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Cite this article as:: Amin A, Plimack ER, Ernstoff MS, et al

Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study

Journal for ImmunoTherapy of Cancer 2019;7:73. doi: 10.1186/s40425-019-0559-3

Log in using your username and password

Main menu

Log in using your username and password

You are here

This article has a correction. Please see:

Download to a citation manager

Read the full text or download the PDF:

Log in using your username and password